FINHUB Insights

LLY · Q2 FY26 · Apr 1 – Jun 30, 2026

Eli Lilly Q2 FY26: where the revenue came from and where it went

Eli Lilly Q2 FY26: revenue $23.0B (+48% year over year). Net profit $7.1B. Largest cohort Mounjaro $9.9B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2026
Reported
Aug 5, 2026 10-Q
Sankey diagram of Eli Lilly's income statement for Q2 FY26: revenue of $23.0 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$23.0B +48% year over year
Gross profit$19.7B 86% margin
Operating profit$9.0B 39% margin
Net profit$7.1B 31% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
ItemValueShare of revenueYear over year
Revenue 23.0 100% +48%
Mounjaro 9.9 43% +91%
Zepbound 4.9 21% +46%
Other 2.1 9%
Verzenio 1.5 6% −1%
Jardiance 1.2 5% +79%
Trulicity 1.2 5% +12%
Other oncology 1.1 5% +19%
Cardiometabolic health 1.0 4% +5%
Cost of revenue−3.314%
Gross profit19.786% margin+2pp
SG&A−3.415%−3pp
Other−7.332%+0pp
Operating profit9.039% margin−5pp
Tax−2.2
Net profit7.131%−6pp
Filing on EDGAR More quarters of LLY

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.